Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Cancer care

Pharmaceutical firms cut price of cancer drugs for African countries

Two major pharmaceutical companies are to cut the price of cancer drugs to sub-Saharan African countries following a deal brokered by the American Cancer Society (ACS) and the Clinton Health Access Initiative (CHAI).

The agreement with US pharmaceutical giant Pfizer and Indian pharmaceutical company Cipla will set ‘competitive prices’ for 16 cancer treatment medications, including chemotherapies, for health providers in Ethiopia, Nigeria, Kenya, Uganda, Rwanda and Tanzania.

The initiative is modelled on the campaign to improve access to HIV medicines in Africa, and it will be supported by IBM Health Corps, who will provide free chemotherapy forecasting software to help countries quantify their cancer medicine needs and plan budgets and procurement.

An estimated 44% of all cancer cases in sub-Saharan Africa each year occur in the six targeted countries, and this agreement is part of a wider effort by ACS and supported by CHAI to improve the market environment for cancer care in Africa.

Gary M Reedy, chief executive of the ACS, said: “Every person with cancer deserves access to treatment, no matter where they live. Collaborating with companies like Pfizer and Cipla is a critical next step toward levelling the playing field for people with cancer and saving lives in this part of the world.”

In 2012, there were an estimated 626,000 new cases of cancer and 447,000 cancer deaths in sub-Saharan Africa, a figure which is set to double by 2030 because of ageing populations.

But the ACS says global funding for cancer prevention and treatment in lower-income countries is far lower than for other diseases including HIV, malaria and tuberculosis.

Trudi Hilton, a pharmacist consultant in resource-limited settings, welcomed the initiative, but warned that cost was not the only limiting factor in improving access to medicines.

“Access to medicines has a lot to do with health literacy — patients being aware of symptoms and how to report them in a timely manner so that they can access appropriate healthcare,” she said.

“Pharmacists are essential health educators as they may be the first port of call in community settings but only if they actively engage local populations and are not seen as purely profiting from ill-health through sales of medicines.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20203722

Readers' comments (1)

  • Michael Achiampong

    I am heartened to read of this development for African populations. I also agree with the necessity to improve the health literacy and that locally based healthcare practitioners can facilitate this. Now, how about other pharma/biotech/start-ups in non-communicable and communicable diseases following suit in making their medicines and devices etc more affordable? And therefore more accessible to other low-to-middle income populations?

    Unsuitable or offensive? Report this comment

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Pills in hand ss 17

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.